CASC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cascadian Therapeutics Inc's net foreign currency exchange gain & loss for the three months ended in Dec. 2016 was USD 0.00 Mil. Its net foreign currency exchange gain & loss for the trailing twelve months (TTM) ended in Dec. 2016 wa USD 0.00 Mil.
We are exposed to fluctuations in foreign exchange rates on the revaluation of monetary assets and liabilities denominated in currencies other than the local functional currency of the relevant subsidiary. This includes third party receivables and payables, including our Senior Notes which are denominated in Euros, as well as intercompany loans. Our subsidiaries generally receive funding via loans that are denominated in currencies other than the dollar, and any change in the relevant exchange rate will require us to recognize a transaction gain or loss on revaluation.
Cascadian Therapeutics Inc Net Foreign Currency Exchange Gain for the trailing twelve months (TTM) ended in Dec. 2016 was 0 (Mar. 2016 ) + 0 (Jun. 2016 ) + 0 (Sep. 2016 ) + 0 (Dec. 2016 ) = USD 0.00 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
Cascadian Therapeutics Inc Annual Data
Cascadian Therapeutics Inc Quarterly Data